Semaglutide patent expiry could slash Indian weight-loss drug costs by 70%

A hospital in South Delhi known for treating diabetes has been fielding calls all week—most of them about weight-loss drugs. Tomorrow, March 20, the patent on semaglutide expires in India, and that single date is reshaping the economics of a market that has been locked behind premium pricing for years.

Semaglutide is the molecule inside Wegovy and Ozempic, drugs that have become synonymous with weight loss in the global conversation. It works by mimicking a hormone that tells your body to slow digestion and feel full faster, for longer. Right now, a month's supply costs between 10,000 and 25,000 rupees—a price point that keeps the drug out of reach for most Indians. When the patent wall comes down tomorrow, Indian generic manufacturers are expected to flood in, and the math changes dramatically. Analysts predict prices will fall by half to two-thirds, landing somewhere between 3,000 and 5,000 rupees monthly. That shift alone could transform weight-loss treatment from a luxury good into something ordinary people might actually afford.

The pharmaceutical industry is calling it a magic pill moment. Brokerages are projecting the Indian semaglutide market could hit a billion dollars by 2030—a staggering figure for a drug class that barely existed in the country's consciousness five years ago. The surge in hospital inquiries is real. People are waiting for tomorrow. They are ready to buy.

But the path from patent expiry to a crowded marketplace is not straight. Sarabjit Kour Nangra, an independent equity analyst, cautions that predicting how many manufacturers will actually enter is nearly impossible. The molecule itself is complex to manufacture. Secondary patents—intellectual property protections that sit alongside the main patent—may still block certain routes to production. Some companies will likely adopt a wait-and-see posture, watching to see if early entrants face regulatory or manufacturing headaches before committing their own capital. The initial wave of generics may be smaller than optimists expect.

Regulatory friction is real. On March 10, the Central Drugs Standard Control Organization issued guidance warning manufacturers against aggressive promotion. No influencer endorsements. No disease awareness campaigns designed to drum up demand. No digital outreach that overstates benefits or promises guaranteed weight loss. The regulator is essentially saying: you can make the drug, you can sell it, but you cannot market it the way the brand did. That constraint will shape how quickly the market actually grows.

Smaller manufacturers face an additional burden. The regulatory approval process is demanding. The drugs carry side effects that require monitoring and disclosure. The manufacturing process is unforgiving—one misstep in formulation and the batch fails. These are not obstacles that stop the largest players, but they are real enough to keep smaller companies on the sidelines, at least initially.

What happens next depends on how many manufacturers decide the opportunity is worth the risk. The price floor is set. The demand is there. But between tomorrow and the billion-dollar market of 2030 lies a gap filled with regulatory decisions, manufacturing challenges, and the simple question of whether Indian pharma companies will move fast or move cautiously. The phone at that South Delhi hospital will keep ringing. The answer to whether those callers can actually afford the drug they are asking about will depend on how many generic makers decide to show up.